Rocket Fuel
Advanced Search
Print    Email
Decrease (-) Restore Default Increase (+)
Find a Physician

Lymphoma Clinical Trials

Please check with your doctor or call 1-855-HCH-HOPE (424-4673) to find out if you qualify for any of these studies.

Trial  #

Trial Sub-type

Title

 ECOG E1411

Mantle Cell Lymphoma
Front - line Patients ≥ 60

Intergroup Randomized Phase II Four Arm Study In Patients ³ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR).

B3281006
Sponsor: Pfizer

Follicular Lymphoma
First line

A phase 3, randomized, double-blind study of PF-05280586 in combination with cyclophosphamide, vincristine, and prednisone (CVP) versus rituximab with CVP for first-line treatment of patients with CD20-positive follicular lymphoma.

  Holy Cross Hospital
  Holy Cross Germantown Hospital
  Icon-LinkedIn.png 

© 2015  Holy Cross Health | 1500 Forest Glen Road, Silver Spring, MD 20910 | 301-754-7000
trinity-health.org